Julia Chisholm, PhD, FRCPCH, The Royal Marsden NHS Foundation Trust, explains some of the ongoing work into improving treatment in rhabdomyosarcoma. She describes various potential avenues, including work investigating drugs that could potentiate the effects of radiotherapy, as well as work looking at the potential for immunotherapy and CAR-T cell approaches. Furthermore, she explains how molecular profiling could help in the development of more specific, targeted approaches against rhabdomyosarcoma in the future. Patients may require different approaches for optimal treatment, with the ultimate goal being an individualized and personalized approach. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).